This is a side-by-side of what is documented, not a ranking. Different compounds are studied for different things, in different people, at different amounts. A row that looks stronger for one compound does not make it the better choice for anyone.
| ARA-290 | Larazotide | |
|---|---|---|
| Highest evidence tier on the page | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. | E2 Human clinical evidence Registered or peer-reviewed human trial with reported results. |
| Regulatory status | Not FDA-approved; investigational (Phase 2 clinical stage); FDA orphan drug and fast track designations reported for sarcoidosis-associated small fiber neuropathy | Not FDA-approved; Phase 3 celiac disease trial (NCT03569007) terminated in 2022 after interim futility analysis; no active pivotal trial identified |
| Research area | Tissue repair and recovery | Tissue repair and recovery |
| Regulator-approved dose on file | No approved dose | No approved dose |
| Molecular formula | C51H84N16O21 | C32H55N9O10 (free peptide, per PubChem) |
| Molar mass | Approximately 1,257.32 g/mol | Not reliably established |
| CAS number | 1208243-50-8 | 881851-50-9 |
| Registered trials on this site | 1 in the tracker | 5 in the tracker |
| Furthest registered phase | Phase 2 | Phase 3 |
| Trials currently active | 0 | 0 |
| Trial sponsors | Araim Pharmaceuticals, Inc. | Massachusetts General Hospital, 9 Meters Biopharma, Inc. |
| What is not known | No currently active, later-phase registered clinical trial for cibinetide was identified as of this review; the most recent completed trial located (NCT02039687) finished in 2015, and it is unclear from public sources whether Araim Pharmaceuticals is continuing active clinical development. The FDA orphan drug and... | Larazotide's trial record shows an inconsistent efficacy signal: some Phase 1b/2b gluten-challenge and Phase 2 dose-ranging endpoints reportedly reached statistical significance, but the definitive Phase 3 trial for persistent symptoms in celiac disease on a gluten-free diet (NCT03569007) was terminated in 2022 after an interim... |
Full pages: ARA-290 and Larazotide. See also the clinical trial tracker and how we grade evidence.
Educational reference, not medical advice. Trial data from ClinicalTrials.gov. Everything else is drawn from the compound pages on this site, each of which cites its sources.
